(Q43733972)

26 November 2017

title

Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol (English)

1 reference

26 November 2017

0 references

1

1 reference

26 November 2017

Peter J Weiden

2

1 reference

26 November 2017

Antony D Loebel

3

1 reference

26 November 2017

Lewis E Warrington

4

1 reference

26 November 2017

Eric J Watsky

5

1 reference

26 November 2017

Cynthia O Siu

6

1 reference

26 November 2017

language of work or name

1 reference

7 May 2009

1 reference

The International Journal of Neuropsychopharmacology

26 November 2017

published in

1 reference

26 November 2017

volume

12

1 reference

26 November 2017

issue

9

1 reference

26 November 2017

page(s)

1233-1248

1 reference

Remission criteria for schizophrenia: evaluation in a large naturalistic cohort

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

From the World Health Organization. Mental health: new understanding, new hope

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Symptom rating scales and outcome in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Long-term course of schizophrenic illness: Bleuler's study reconsidered

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Long-term outcome of schizoaffective and schizophrenic disorders: a comparative study. I. Definitions, methods, psychopathological and social outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Mediators and moderators of treatment effects in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Intermittent vs maintenance medication in schizophrenia. Two-year results

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

Global assessment of functioning. A modified scale

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709000352

7 January 2021

10.1017/S1461145709000352

Identifiers

DOI

1 reference

26 November 2017

1 reference